United States Patent 6,348,211 (methylphenidate topical/transdermal “flexible finite system”) scope, claim-by-claim coverage, and enforcement landscape
United States Patent 6,348,211 is an IMPLICIT “product-by-parameter” estate covering topical and transdermal methylphenidate delivery using a flexible, finite system, with performance limits tied to kinetics (substantially zero-order over ≥10 hours), delivery physiology (skin/mucosa or flux/blood level ranges), and formulation exclusions (substantially free of ritalinic acid at manufacture). The independent claim is composition-centric (claim 1) and the estate is strengthened by (i) dependent claim selectors for methylphenidate form (base/basic salt/ester), enantiomeric content, crystal-free condition, and adhesive subclasses; and (ii) method-of-use claims that map directly to ADHD/ADD and transdermal delivery rates/flux.
This is a relatively narrow claim architecture for enforceability: it is broad on “topical application” and “transdermal delivery” concepts but narrow on specific quantitative constraints (ratios, time windows, flux ≥5 μg/cm²/hr, blood level 1–6 ng/mL for ≥10–20 hours, dosing rate windows) and on manufacturing-time chemical condition (substantially free of ritalinic acid).
What is US Patent 6,348,211 and what is it claiming at a high level?
Core invention:
A methylphenidate topical/transdermal composition in a flexible, finite system using specific adhesive components and ratios to deliver methylphenidate for at least 10 hours with substantially zero-order kinetics, while being substantially free of ritalinic acid at the time of manufacture.
Structure of the claim set (based on the provided claims):
- Composition independent claim: claim 1 (topical application)
- Composition dependent/expansion claims: claims 2–27 (methylphenidate form, quantity per skin area, adhesive types, delivery rates, crystal-free requirement)
- Transdermal composition independent claim: claim 22 (flux ≥5 μg/cm²/hr for ≥10 hours to achieve therapeutic blood levels)
- Transdermal composition dependent claims: claims 23–26 (children dosing; dose/flux/time; specific blood level ranges)
- Method-of-use independent claims: claim 28 (treating ADD/ADHD with topical administration under the claim 1 formulation constraints), claim 30–31 (transdermal treatment with flux/rate thresholds)
- Method-of-use dependent claims: claim 29 (treating ADD/ADHD with broad delivery-rate capability, without ritalinic acid and ratio constraints)
Key legal-enablement signals embedded in the claim language:
- “substantially zero order kinetics” (performance-defined)
- “flexible, finite system” (product architecture term)
- “proportion of methylphenidate:silicone adhesive:acrylic adhesive (wt % dry)” (parameter-defined composition)
- “substantially free of ritalinic acid at the time of manufacture” (manufacturing condition limitation)
- “substantially comprises the d-threo-methylphenidate enantiomer” (enantiomer selection)
- “substantially free of crystals” (physical form limitation)
Claim 1 coverage: what methylphenidate topical composition is protected?
Claim 1: composition for topical application
Claim 1 requires all of the following:
- Topical composition for methylphenidate
- Methylphenidate + pharmaceutically acceptable adhesive carrier
- Carrier in a flexible, finite system
- Methylphenidate amount sufficient to achieve substantially zero-order kinetics delivering to skin or mucosa for ≥10 hours
- Quantitative ratio (wt % dry):
- methylphenidate : silicone adhesive : acrylic adhesive = about 5–30 : 0–70 : 0–70
- Manufacturing condition: composition is substantially free of ritalinic acid at the time of manufacture
Scope notes for infringement mapping:
- “skin or mucosa” means coverage likely includes both dermatological application and certain mucosal delivery contexts, though practical enforcement depends on actual product design.
- The ratio is very wide (0–70 for silicone and 0–70 for acrylic) but constrained by the methylphenidate portion (5–30). The “about” language adds tolerance.
- The performance requirement (zero-order kinetics over ≥10 hours) can be a strong evidentiary battleground: proving “substantially” and “zero-order” often turns on pharmacokinetic curves and comparator studies.
Which dependent claims narrow Claim 1 into enforceable sub-genres?
Enantiomer and chemical form limitations
- Claim 2: methylphenidate is in base form
Narrowing: eliminates salts/esters unless used under other claims.
- Claim 4: methylphenidate is a base/basic salt combination or an ester
Expands beyond claim 2 into selectable chemical forms.
- Claim 5: methylphenidate substantially comprises the d-threo enantiomer
Narrowing: requires enantiomeric dominance.
Dose-per-area limitation
- Claim 3: methylphenidate base is present at ≥26.4 mg per about 10 cm²
Narrowing: forces a minimum loading tied to a surface area.
Delivery duration selectors
- Claim 13: delivery over ~12–20 hours
- Claim 14: delivery over ~14–16 hours
Narrowing: time window tighter than claim 1’s ≥10 hours.
Crystal/physical state limitation
- Claim 27: topical methylphenidate composition with:
- claim 1-level parameters (flexible finite system; zero-order ≥10h; ratio; ritalinic acid-free at manufacture)
- plus methylphenidate substantially free of crystals
Narrowing: excludes formulations with visible/operative crystallinity.
Expanded dose-rate architecture
- Claims 16–21 provide a second independent “compositional delivery rate” frame (see next section).
Adhesive and bioadhesive selectors
Claims 6–12 map adhesive chemistry to protected embodiments:
- Claim 6: further comprising an adhesive
- Claim 7: adhesive selected from broad classes:
- acrylics
- natural and synthetic rubbers
- bioadhesives
- polysiloxanes
- polyacrylates
- polyvinylpyrrolidones and vinylpyrrolidone copolymers
- styrene block polymers and mixtures
- Claim 8: adhesive includes bioadhesive from:
- natural or synthetic polysaccharides
- polyacrylic acid polymers
- Claim 9: natural polysaccharide is a natural gum
- Claim 10: adhesive includes capped or amine-compatible polysiloxane
- Claim 11: adhesive includes nonfunctional/minimally functional acrylic
- Claim 12: adhesive includes polyacrylate that is non-vinyl acetate containing polymer
Enforcement implication: these are “either/or” buckets with further sub-buckets (e.g., capped polysiloxane). In practice, defendants can try to design around by selecting adhesive chemistries outside these exemplars, or by altering the silicone/acrylic ratio endpoints. But claim 7 is broad in the adhesive class list, so design-around tends to focus on the quantitative ratio and the performance condition rather than the adhesive chemistry taxonomy alone.
Claims 15 and 16: what additional ratios and delivery-rate concepts are protected?
Claim 15: alternate ratio window
- ratio (wt % dry) methylphenidate:silicone adhesive:acrylic adhesive = 20–30 : 30–70 : 10–40
This is narrower than claim 1 and provides a more specific embodiment for enforcement leverage if accused products fall inside that rectangle of formulation space.
Claim 16: composition frame with delivery rate range
Claim 16 is an independent claim (composition) with these key differences from claim 1:
- still requires flexible, finite system
- still requires substantially free of ritalinic acid at manufacture
- adds delivery-rate feasibility: methylphenidate amount permits
- delivery rate ~0.5 mg/24 hours to ~100 mg/24 hours
- retains the same ratio window as claim 1:
- ~5–30 : 0–70 : 0–70 (wt % dry)
Design around implication: a product could meet a flux requirement but avoid claim 16 by targeting a delivery-rate outside 0.5–100 mg/24h or by not meeting the ratio window and ritalinic acid condition.
Claims 17–21: delivery rate and dose ranges
- Claim 17: delivery rate ~2.5–20 mg/24h
- Claims 18 & 20: therapeutically effective dose ~0.05–1.0 mg/kg/day
- Claims 19 & 21: therapeutically effective dose ~0.075–0.3 mg/kg/day
These are outcome-linked dosing windows that narrow the embodiment to systems that can support those dose bands in clinical use or intended dosing regimens.
What does Claim 22 protect: transdermal methylphenidate flux and blood levels?
Claim 22: transdermal delivery composition
Protected subject matter:
- transdermal methylphenidate composition comprising methylphenidate or pharmaceutically acceptable salt
- methylphenidate amount sufficient to provide flux ≥5 μg/cm²/hr
- flux must support therapeutic blood levels for ≥10 hours
Key difference from claim 1: this claim uses transdermal flux and blood-level outcome, not an explicit adhesive ratio. That makes it a different infringement axis: even if a competitor changes adhesive architecture, they can still land in scope if they hit the flux/time/blood-level threshold.
Claims 23–26: transdermal populations and specific PK ranges
- Claim 23: methylphenidate is for children (population-limited claim)
- Claim 24: dose: at least 0.5 mg to a patient over 24 hours with flux ≥5 μg/cm²/hr for ≥10 hours
- Claim 25: blood levels 1–6 ng/mL for ≥10 hours
- Claim 26: blood levels 1–6 ng/mL for ≥20 hours
Enforcement implication: these constraints can be used as “hard numbers” for expert testimony. The likely litigation pattern is:
- plaintiff uses PK bridging to show accused product maintains serum levels within the window,
- defendant tries to show different achieved concentrations or different time-above-threshold profiles.
What do the method claims cover: treatment of ADD/ADHD with transdermal or topical dosing?
Claim 28: method with topical administration under claim 1-like formulation constraints
- treating ADD and ADHD
- topically administering methylphenidate in a flexible, finite system
- methylphenidate amount sufficient for:
- substantially zero-order kinetics for skin/mucosa delivery over ≥10 hours
- formulation ratio ~5–30 : 0–70 : 0–70 (wt % dry)
- substantially free of ritalinic acid at manufacture
This is the most tightly anchored method claim. It is strong when infringement is based on both formulation parameters and pharmacokinetic behavior.
Claim 29: method with a delivery-rate capability frame
- treating ADD/ADHD
- topically administering in a flexible, finite system
- methylphenidate amount sufficient to permit delivery rate ~0.5–100 mg/24h
Notably, claim 29 does not repeat the ritalinic acid-free limitation or the adhesive ratio limitation in the provided text. That broadens the method claim relative to claim 28.
Claim 30: transdermal treatment with rate (flux) threshold
- treating ADD/ADHD
- transdermal administration
- at a rate in excess of 5 μg/cm²/hr
Claim 31: transdermal treatment with mg/kg/day threshold
- treating ADD/ADHD
- transdermal administration
- at a rate in excess of 0.05 mg/kg/day
Enforcement implication: method claims 30 and 31 can be triggered by dosing instructions and real-world use achieving those thresholds, even if formulation details differ, provided proof can tie clinical use to the claimed delivery rates.
How strong is the patent estate’s “design-around resistance”?
What is hardest to copy around
- Ritalinic acid-free at manufacture (explicit exclusion)
This is a manufacturing-time limitation that may be difficult to disprove but also difficult to intentionally meet without controlling upstream chemistry and analytical release criteria.
- Zero-order kinetics over ≥10 hours
Performance claims force PK evidence; defendants must show kinetics diverge meaningfully.
- Specific transdermal flux and blood level windows (claims 22, 25, 26)
These are measurable pharmacology endpoints.
What is easiest to design around
- Adhesive chemistry lists (claims 7–12)
The list is broad; design-around can try to pick adhesives that are not “selected from” the listed group, but because the categories are wide, chemical selection alone may not eliminate infringement if the product still satisfies the ratio and performance limits.
- Dose windows (claims 18–21)
Dose regimens can shift with patient targeting; however, if the accused product’s marketed dosing supports those ranges, it can still be captured.
Internal redundancy
The estate is built with overlapping claim types: composition parameters (claims 1, 16), PK/flux parameters (claims 22, 25, 26), and method-of-use parameters (claims 28, 30, 31). That reduces the ability for a competitor to avoid all claims with a single variable change.
How do these claim elements map to litigation proof? (practical evidentiary checklist)
For composition claims (1, 16, 22):
- Product formulation: percent-by-weight dry contents (to assess methylphenidate:silicone:acrylic ratios)
- Adhesive identification: silicone adhesive presence; acrylic adhesive presence; whether adhesive chemistry falls within claim selectors
- Chemical quality: analytical testing showing “substantially free of ritalinic acid at the time of manufacture”
- PK performance: kinetics profiles confirming “substantially zero-order” over ≥10 hours
- Physical state: for claim 27, evidence of crystallinity status
- Enantiomeric content: for claim 5, d-threo dominance
For method claims (28, 30, 31):
- Labeling and instructions for use
- Real-world administration regimen
- Pharmacology testing or modeling to show transdermal delivery rates:
- claim 30: >5 μg/cm²/hr
- claim 31: >0.05 mg/kg/day
- For claim 28: again ties to formulation constraints and zero-order delivery behavior.
What generic entry risks exist for a methylphenidate transdermal competitor?
Risk drivers that pull competitors into scope:
- Any methylphenidate transdermal system that achieves:
- flux ≥5 μg/cm²/hr for ≥10 hours (claim 22, claim 30 threshold),
- blood levels within 1–6 ng/mL for ≥10–20 hours (claims 25–26),
- plus maintaining the “flexible, finite system” and key manufacturing-time ritalinic acid-free condition if pursued under claims 1/28.
Potential safe harbors (relative, not absolute):
- Formulation that cannot support substantially zero-order kinetics for ≥10 hours (claims 1/28/27).
- Transdermal products with flux below 5 μg/cm²/hr (claim 22 and method claim 30).
- Dosing regimens that operate below 0.05 mg/kg/day (method claim 31).
- Formulations where ritalinic acid is not substantially eliminated at the time of manufacture would fail the “substantially free” limitation, but they would need to accept chemical/quality trade-offs.
What timelines matter: how long does US 6,348,211 typically run?
No filing date, priority, patent term adjustment (PTA), or terminal disclaimer terms were provided in the input. Without those data, the exact expiration and any PTAB/maintenance status cannot be computed from claim text alone.
Key Takeaways
- US 6,348,211 protects methylphenidate topical and transdermal delivery systems defined by (i) performance (zero-order over ≥10 hours; flux/blood-level windows) (ii) formulation architecture (flexible, finite system; silicone and acrylic adhesives with explicit weight dry ratios) and (iii) manufacturing chemistry (substantially ritalinic-acid-free at manufacture).
- The estate is enforceable on multiple axes: composition claims (1, 16, 22), formulation refinements (15, 3, 5, 27), and method claims (28, 29, 30, 31).
- Design-around efforts would need to address at least one of the hard numerical constraints:
- ratio windows (claims 1/15/16),
- transdermal flux ≥5 μg/cm²/hr (claims 22/30),
- blood levels 1–6 ng/mL for ≥10–20 hours (claims 25/26),
- transdermal dosing >0.05 mg/kg/day (claim 31),
- and/or “substantially free of ritalinic acid at manufacture.”
- Because several claims are outcome-defined with measurable thresholds, litigation will likely center on PK/flux testing and manufacturing-time impurity analytics rather than only adhesive chemistry substitution.
FAQs
-
Does US 6,348,211 require “zero-order kinetics” for all its claims?
No. Zero-order kinetics is explicit in claims tied to the topical flexible finite system (e.g., claim 1 and claim 28) and in claim 27, while transdermal claims like claim 22 use flux and blood-level outcomes.
-
Can a competitor avoid infringement by changing adhesive chemistry alone?
Not reliably. Even if adhesive chemistry differs from the exemplified categories, infringement can still occur if the product meets the ratio constraints (where claimed) and the flux/blood-level thresholds (claims 22, 25, 26).
-
What is the tightest set of transdermal constraints in this patent?
Claim 25/26: blood levels in the 1–6 ng/mL range for at least 10 and at least 20 hours, respectively.
-
Is “ritalinic acid substantially free at the time of manufacture” a formulation or process limitation?
It is written as a manufacturing-time condition tied to the composition at manufacture, which makes it a quality/process-adjacent limitation.
-
Which claims are most directly testable in an infringement lab setting?
Claims with explicit numerical thresholds: wt% dry ratios (claims 1, 15, 16), methylphenidate loading per skin area (claim 3), delivery rate windows (claims 16–17), transdermal flux ≥5 μg/cm²/hr (claim 22 and method claim 30), and blood level ranges (claims 25–26).
